Академический Документы
Профессиональный Документы
Культура Документы
One of the important class of lymphoma is large cell lymphoma. In this class, size of white blood
cells (lymphocytes) is increased in uncontrollable manner and become cancer. An average size of
WBC in large cell lymphoma is around 17-20 micrometers. Large cell lymphoma is one of the
chronic and most severe types of lymphomas and possesses a moderate rate of morbidity. The
disease is diagnosed by using laboratory tests (CBC, flow cytometry, serum electrolyte tests and
others), biopsy and lumbar puncture, and imaging studies.
The market of large cell lymphoma is segmented on the basis of types of cells in which large cell
lymphoma is observed, such as T-ell and B-cell lymphoma. In T-cell lymphoma, T-cells
lymphocytes are enlarged in size and multiplied rapidly. Anaplastic large cell lymphoma is an
example of T-cell large-cell lymphoma. B-cell lymphoma is divided further on the basis of
location of types of cells, such as diffuse large-cell lymphoma, Burkitts large-cell lymphoma,
primary medistinal large-cell lymphoma, immunoblastic lymphoma, angiocentric lymphoma,
follicular large-cell lymphoma, primary splenic lymphoma, T-cell rich B-cell lymphoma and
intravascular large-cell lymphoma. The market is also segmented on the basis of treatments
available, such as, radiation therapy, mild chemotherapies, topical treatments, and biological
therapies.
A medicinal (chemotherapy) treatment includes drugs such as cytarabine, dexomethasone,
ifosfamide, etoposide, methotrexate, cisplatin and others. Furthermore, the market is segmented
on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World
(RoW). The North American region is the most dominating market in the world, owing to
exponentially growing incidence proportion with lymphoma disorders. On the other hand, AsiaPacific and RoW regions are the most promising markets in the upcoming period, owing to rise
in awareness of therapeutics, rapid increase in incidences of lymphomas and growth of medical
infrastructure.
The market is expected to grow exponentially during the forecast period 2014 - 2020. This
growth is driven by many influencing factors, such as, rising prevalence of cancer and
lymphomas, extensive R&D practices, increase in medical expenditure, and increase in the
awareness amongst the population about the disease, its consequences and treatments available.
Rising prevalence of the disease is one of the most important cause of market growth. According
to statistics presented by the U.K. Leukemia and Lymphoma Research, around 11,700 people in
the U.K. are diagnosed with lymphoma every year. Hence, this rising prevalence will fuel the
growth of market during the study period 2014 - 2020.
In addition, extensive R&D practices is another important market driver. As of now, large
number of products, such as, ofatumumab, ibrutinib, bortezomib, CTL-019, and vorinostat
amongst others, are under pipeline studies and are expected to enter in the market during the
forecast period. However, high cost of R&D and treatment, threat of failure during clinical trials,
limited technological intervention in certain region of the world are major restraints of the
market.
To Get Download Full Report with TOC: http://www.mrrse.com/sample/toc/210299
Some of the major players operating and engaged in R&D includes Novartis International AG,
Merck & Co., Inc., Gilead Sciences, Inc., AstraZeneca plc, GSK plc, and Sanofi amongst others.
This research report analyzes this market depending on its market segments, major geographies,
and current market trends. Geographies analyzed under this research report include
North America
Asia Pacific
Europe
Rest of the World
This report is a complete study of current trends in the market, industry growth drivers, and
restraints. It provides market projections for the coming years. It includes analysis of recent
developments in technology, Porters five force model analysis and detailed profiles of top
industry players. The report also includes a review of micro and macro factors essential for the
existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
Contact Us:
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Toll Free: 866-997-4948
(USA-CANADA)
Tel: +1-518-618-1030
Website: http://www.mrrse.com/